RU2019103297A - Гастроретентивные составы для перорального введения и пути их применения - Google Patents
Гастроретентивные составы для перорального введения и пути их применения Download PDFInfo
- Publication number
- RU2019103297A RU2019103297A RU2019103297A RU2019103297A RU2019103297A RU 2019103297 A RU2019103297 A RU 2019103297A RU 2019103297 A RU2019103297 A RU 2019103297A RU 2019103297 A RU2019103297 A RU 2019103297A RU 2019103297 A RU2019103297 A RU 2019103297A
- Authority
- RU
- Russia
- Prior art keywords
- dosage unit
- pharmaceutical dosage
- cannabinoid
- polymer
- gastroretentive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360744P | 2016-07-11 | 2016-07-11 | |
| US62/360,744 | 2016-07-11 | ||
| PCT/IL2017/050783 WO2018011798A1 (en) | 2016-07-11 | 2017-07-11 | Oral gastroretentive formulations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019103297A true RU2019103297A (ru) | 2020-08-11 |
| RU2019103297A3 RU2019103297A3 (cg-RX-API-DMAC7.html) | 2020-11-06 |
Family
ID=59388117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019103297A RU2019103297A (ru) | 2016-07-11 | 2017-07-11 | Гастроретентивные составы для перорального введения и пути их применения |
Country Status (17)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018152334A1 (en) * | 2017-02-15 | 2018-08-23 | Molecular Infusions, Llc | Formulations |
| BR102018002843A2 (pt) * | 2018-02-09 | 2019-08-27 | Prati, Donaduzzi & Cia Ltda | composição farmacêutica e uso da mesma |
| WO2020037410A1 (en) * | 2018-08-20 | 2020-02-27 | Hexo Operations Inc. | Cannabis-infused product with enhanced cannabinoid profile user experience |
| GB2584341B (en) * | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| CN114650809A (zh) | 2019-10-03 | 2022-06-21 | 斯塔顿治疗公司 | 屈大麻酚的透皮递送 |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| JP2022551730A (ja) | 2019-10-14 | 2022-12-13 | パイク セラピューティクス,インコーポレイテッド | カンナビジオールの経皮送達 |
| US20210177740A1 (en) * | 2019-12-11 | 2021-06-17 | Joel Studin | Transpore delivery of cannabinoid and uses thereof |
| EP4084790A1 (en) * | 2020-01-02 | 2022-11-09 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Floating drug delivery systems comprising cannabinoids |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023272335A1 (en) * | 2021-06-30 | 2023-01-05 | Emyria | Cannabidiol formulation comprising a matrix pellet forming excipient |
| CN114796142A (zh) * | 2022-04-08 | 2022-07-29 | 黄山学院 | 萘普生胃漂浮片及其制备方法 |
| TW202430130A (zh) * | 2022-10-18 | 2024-08-01 | 大陸商南京三迭紀醫藥科技有限公司 | 用於胃滯留的口服藥物劑型 |
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03163011A (ja) * | 1989-08-31 | 1991-07-15 | Yamanouchi Pharmaceut Co Ltd | 胃内滞留デバイス |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| US10004684B2 (en) * | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
| US9265724B2 (en) * | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| PT1903866E (pt) | 2005-11-07 | 2016-06-09 | Murty Pharmaceuticals Inc | Distribuição melhorada de tetra-hidrocanabinol |
| DK2997953T3 (en) | 2006-01-18 | 2019-04-15 | Intec Pharma Ltd | ADMINISTRATION ORAL ADMINISTRATION |
| DK2276473T3 (en) * | 2008-04-18 | 2017-01-09 | Intec Pharma Ltd | GASTRORETENTIV drug TO carbidopa / levodopa |
| WO2010064139A2 (en) * | 2008-12-04 | 2010-06-10 | Intec Pharma Ltd. | Zaleplon gastroretentive drug delivery system |
| WO2011048494A2 (en) | 2009-10-19 | 2011-04-28 | Intec Pharma Ltd. | Novel gastroretentive dosage forms of poorly soluble drugs |
| US20140017303A1 (en) * | 2010-11-01 | 2014-01-16 | Intec Pharma Ltd. | Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms |
| US8808734B2 (en) | 2011-07-11 | 2014-08-19 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
| KR20160002709A (ko) * | 2013-02-12 | 2016-01-08 | 코버스 파마수티컬스, 아이엔씨. | 초고순도 테트라하이드로카나비놀-11-오익산 |
| WO2015025312A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
-
2017
- 2017-07-11 RU RU2019103297A patent/RU2019103297A/ru not_active Application Discontinuation
- 2017-07-11 NZ NZ750422A patent/NZ750422A/en unknown
- 2017-07-11 AU AU2017296351A patent/AU2017296351A1/en not_active Abandoned
- 2017-07-11 KR KR1020197002888A patent/KR20190026799A/ko not_active Ceased
- 2017-07-11 CN CN201780041708.3A patent/CN109414403A/zh active Pending
- 2017-07-11 JP JP2018568785A patent/JP2019527208A/ja active Pending
- 2017-07-11 WO PCT/IL2017/050783 patent/WO2018011798A1/en not_active Ceased
- 2017-07-11 CA CA3027700A patent/CA3027700A1/en not_active Abandoned
- 2017-07-11 MX MX2019000348A patent/MX2019000348A/es unknown
- 2017-07-11 SG SG10202100182TA patent/SG10202100182TA/en unknown
- 2017-07-11 EP EP17743090.7A patent/EP3481371A1/en not_active Withdrawn
- 2017-07-11 US US16/316,390 patent/US20190224118A1/en not_active Abandoned
- 2017-07-11 BR BR112018077541-0A patent/BR112018077541A2/pt not_active Application Discontinuation
- 2017-07-11 SG SG11201811209QA patent/SG11201811209QA/en unknown
-
2019
- 2019-01-02 IL IL264065A patent/IL264065A/en unknown
- 2019-01-09 PH PH12019500061A patent/PH12019500061A1/en unknown
- 2019-01-15 ZA ZA2019/00275A patent/ZA201900275B/en unknown
- 2019-01-23 CO CONC2019/0000643A patent/CO2019000643A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019527208A (ja) | 2019-09-26 |
| CA3027700A1 (en) | 2018-01-18 |
| ZA201900275B (en) | 2020-05-27 |
| NZ750422A (en) | 2021-10-29 |
| BR112018077541A2 (pt) | 2019-04-30 |
| SG11201811209QA (en) | 2019-01-30 |
| WO2018011798A1 (en) | 2018-01-18 |
| PH12019500061A1 (en) | 2019-10-14 |
| MX2019000348A (es) | 2019-03-28 |
| RU2019103297A3 (cg-RX-API-DMAC7.html) | 2020-11-06 |
| SG10202100182TA (en) | 2021-02-25 |
| AU2017296351A1 (en) | 2019-02-28 |
| EP3481371A1 (en) | 2019-05-15 |
| CN109414403A (zh) | 2019-03-01 |
| KR20190026799A (ko) | 2019-03-13 |
| CO2019000643A2 (es) | 2019-04-30 |
| IL264065A (en) | 2019-01-31 |
| US20190224118A1 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527208A5 (cg-RX-API-DMAC7.html) | ||
| JP6325148B2 (ja) | 注意欠陥障害の処置のための方法および組成物 | |
| US9980902B2 (en) | Method for treating intestinal fibrosis | |
| US9999651B2 (en) | Composition comprising oil drops | |
| ES2360423T3 (es) | Preparaciones de liberación controlada de oxcarbazepina que tienen perfil de liberación sigmoidal. | |
| JP4865945B2 (ja) | 経口の延長放出性医薬品剤形 | |
| JP5911969B2 (ja) | 心臓血管障害の治療方法 | |
| KR20100014629A (ko) | 타크로리무스의 변형제형 | |
| JP2014012692A (ja) | 食物の摂取から独立した消化器疾患の治療方法 | |
| JP2018500353A (ja) | 回腸−空腸薬物送達用組成物 | |
| JP2007528901A5 (cg-RX-API-DMAC7.html) | ||
| CN109414403A (zh) | 口服胃滞留制剂及其用途 | |
| US20170119680A1 (en) | Extended release film-coated capsules | |
| JP2020510000A (ja) | フロルグルシノールおよびトリメチルフロログルシノールの医薬製剤 | |
| WO2009148990A1 (en) | Pulsatile release of valsartan | |
| ES2408343A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| RU2577164C2 (ru) | Таблетки с регулируемым по месту и времени высвобождением глюкокортикоида в желудочно-кишечном тракте | |
| US11052048B2 (en) | Esomeprazole-containing complex capsule and preparation method therefor | |
| TW201711683A (zh) | 含有達方吡啶的緩釋口服劑型及其用途 | |
| AU2017252407A1 (en) | Oral pharmaceutical compositions of nicotinamide | |
| RU2021102950A (ru) | Твердые фармацевтические композиции для лечения вируса гепатита с | |
| TW201609196A (zh) | 控制釋放製劑及其製備方法 | |
| EP3145500A1 (en) | Celecoxib formulations useful for treating colorectal cancer | |
| HK40006608A (en) | Esomeprazole-containing complex capsule and preparation method therefor | |
| JP2021528483A (ja) | 下部胃腸管への医薬の送達のための剤形 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210920 |